FDA approves RDUS osteoporosis drug • Radius Health (RDUS +10.5%) heads north on a 4x surge in volume in response to the FDA's approval of TYMLOS (abaloparatide) injection for the treatment of postmenopausal women with osteoporosis at high risk of fracture. • The company will host a webcast on Monday, May 1, at 7:30 am ET to discuss the approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.